Crucial Clinical Data Release Looms for Corbus Shares
Published on 10/15/2025 at 12:00 | Redaktion boerse-global.de
Investors in Corbus Pharmaceuticals are bracing for a pivotal market catalyst this weekend. The biotechnology firm is scheduled to present significant clinical trial results for its oncology drug candidate CRB-701 at the ESMO congress in Berlin. Despite the abstract’s publication yesterday, market reaction remained muted, with shares closing marginally lower at $16.25, representing a 0.43% decline.
Beyond the immediate focus on CRB-701, Corbus maintains a robust financial foundation. The company’s second-quarter 2025 report revealed a net loss of $17.7 million, offset by substantial cash reserves of $116.6 million. This positions the company with an operational runway secured through the second quarter of 2027.
The development pipeline extends further than its lead cancer therapy. Corbus is concurrently advancing CRB-913, a treatment targeting obesity, and... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
